The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype

2018 ◽  
Vol 18 (2) ◽  
pp. e219-e229 ◽  
Author(s):  
Naoki Hayashi ◽  
Yuko Takahashi ◽  
Naoko Matsuda ◽  
Hiroko Tsunoda ◽  
Atsushi Yoshida ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Primary Breast Cancer ◽  
Breast Cancer Subtype ◽  
Tumor Stage ◽  
Nodal Status ◽  
Prognostic Effect ◽  
Cancer Subtype

scholarly journals Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer

2010 ◽  
Vol 1 (5) ◽  
pp. 747-754 ◽  
Author(s):  
REIKI NISHIMURA ◽  
TOMOFUMI OSAKO ◽  
YASUHIRO OKUMURA ◽  
MITSUHIRO HAYASHI ◽  
YASUO TOYOZUMI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Primary Breast Cancer ◽  
Breast Cancer Subtype ◽  
Recurrence Time ◽  
Ki 67 ◽  
Cancer Subtype

Adjuvant Chemotherapy: Which Patient? What Regimen?

2013 ◽  
pp. 3-8 ◽  
Author(s):  
Natalie Turner ◽  
Laura Biganzoli ◽  
Luca Malorni ◽  
Ilenia Migliaccio ◽  
Erica Moretti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Breast Cancer Subtype ◽  
Tumor Biology ◽  
Patient Characteristics ◽  
Tumor Stage ◽  
Luminal A ◽  
Genomic Analyses ◽  
Cancer Subtype ◽  
Clinicopathologic Factors

In the past, treatment decisions regarding adjuvant chemotherapy in early breast cancer (EBC) were made solely based on clinicopathologic factors. However, with increased awareness of the importance of underlying tumor biology, we are now able to use genomic analyses to determine molecular breast cancer subtype and thus identify patients with tumors that are chemotherapy resistant and unlikely to benefit from the addition of chemotherapy. Although genomics has allowed some patients to avoid chemotherapy—specifically those with luminal A–like breast cancer—these assays do not indicate which regimen is most appropriate. For this, consideration must be given to the combination of underlying tumor biology, tumor stage, and patient characteristics, such as age and tolerability of side effects.

scholarly journals Performance of Mid‐Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype

2017 ◽  
Vol 22 (4) ◽  
pp. 394-401 ◽  
Author(s):  
Rosalind P. Candelaria ◽  
Roland L. Bassett ◽  
William Fraser Symmans ◽  
Maheshwari Ramineni ◽  
Stacy L. Moulder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Breast Cancer Subtype ◽  
Breast Ultrasound ◽  
Axillary Ultrasound ◽  
Cancer Subtype ◽  
Response To Neoadjuvant Chemotherapy

Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?

2018 ◽  
Vol 25 (12) ◽  
pp. 3535-3540 ◽  
Author(s):  
Lucy M. De La Cruz ◽  
Michael O. Harhay ◽  
Paul Zhang ◽  
Stacy Ugras
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Breast Cancer Subtype ◽  
Cancer Subtype
Sign in / Sign up

Export Citation Format

Share Document